Contineum Therapeutics, Inc. (CTNM) vs DiaMedica Therapeutics Inc. (DMAC)
A side-by-side comparison of Contineum Therapeutics, Inc. and DiaMedica Therapeutics Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CTNM
Contineum Therapeutics, Inc.
$12.30HealthcareDelayed quote: Oct 6, 2026, 10:05 AM EDT
DMAC
DiaMedica Therapeutics Inc.
$8.49HealthcareDelayed quote: Oct 6, 2026, 10:05 AM EDT
Total return — CTNM vs DMAC
growth of $100 · dividends reinvested · last 2yCTNM -17.4% (-9.1%/yr)DMAC +208.4% (+75.6%/yr)DMAC compounded faster over this window
CTNM DMAC
CTNM vs DMAC: by the numbers
- •CTNM is the larger company ($463M vs $457M market cap).
Metrics side by side
Valuation
| Metric | CTNM | DMAC |
|---|---|---|
| P/B ratio | 1.93 | 11.93 |
Profitability
| Metric | CTNM | DMAC |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -24.02% | -97.92% |
| ROIC | -27.22% | -100.87% |
Growth (annualized)
| Metric | CTNM | DMAC |
|---|---|---|
| Total return CAGR (5Y) | N/A | 16.41% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.